NCT00004032View on ClinicalTrials.gov

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 1997

Primary Completion Date

April 30, 2004

Conditions
Recurrent Ovarian Epithelial Cancer
Interventions
BIOLOGICAL

ALVAC-hB7.1

Given IP

BIOLOGICAL

recombinant interferon gamma

Given IP

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00004032 - Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter